Interactive effects of (±)-trans-U50488 and its stereoisomers with cannabinoids.

Pharmacology, Biochemistry, and Behavior
Laura L ErwinPeter J Winsauer

Abstract

The adverse effects of mu opioid agonists have spurred a renewed interest in using kappa opioid receptor (KOR) agonists as analgesics. KOR agonists also have potential for development as diuretics for the treatment of edema and hypertension. Here, we evaluated the discriminative stimulus, antinociceptive, and diuretic effects of the kappa agonist (±)-trans-U-50488 and its stereoisomers (-)-(1S,2S)-U-50488 or (+)-(1R,2R)-U-50488) alone and in combination with the cannabinoid agonist (-)-CP 55,940. To establish (±)-U-50488 as a discriminative stimulus, rats (n = 12) were trained to discriminate intraperitoneal (i.p.) administration of 5.6 mg/kg of (±)-trans-U-50488 from saline under a fixed-ratio 20 (FR-20) schedule of food reinforcement. Then, antinociception was assessed using two procedures: warm water tail withdrawal and von Frey paw withdrawal. Diuretic effects were assessed in separate rats (n = 6/group). Doses of (±)-U-50488 and (-)-U-50488 that served as discriminative stimuli produced significant increases in urine output, but at lower doses than those that produced antinociception. In contrast, (+)-U-50488 alone had no discriminative stimulus or diuretic effects at the doses tested, but did produce antinociception in th...Continue Reading

References

Mar 1, 1990·Proceedings of the National Academy of Sciences of the United States of America·M HerkenhamK C Rice
Aug 15, 1986·Science·A PfeifferH M Emrich
Jul 1, 1987·Medicinal Research Reviews·E J Ariëns
Jan 1, 1973·Progress in Brain Research·H BarryJ L Perhach
Jul 1, 1994·Journal of Neuroscience Methods·S R ChaplanT L Yaksh
Jul 4, 1996·European Journal of Pharmacology·S J GatleyA Makriyannis
Aug 1, 1996·British Journal of Pharmacology·R G Pertwee, S R Fernando
Aug 29, 1996·European Journal of Pharmacology·Y KolesnikovG W Pasternak
Jan 1, 1997·Pharmacology & Therapeutics·R G Pertwee
May 31, 2002·Pharmacological Reviews·A C HowlettR G Pertwee
May 14, 2004·The Journal of Neuroscience : the Official Journal of the Society for Neuroscience·Mei XuCharles Chavkin
Jun 14, 2005·The Clinical Journal of Pain·Michael G Byas-SmithGeorge Cotsonis
Dec 21, 2005·Proceedings of the National Academy of Sciences of the United States of America·Jane E LaucknerKen Mackie
Jun 10, 2008·The Journal of Pharmacology and Experimental Therapeutics·Melissa A BurmeisterDaniel R Kapusta
Nov 8, 2008·The AAPS Journal·Emily O Dumas, Gary M Pollack
Sep 29, 2012·The Journal of Pharmacology and Experimental Therapeutics·Carol A ParonisJack Bergman
Oct 9, 2013·European Journal of Pharmacology·Girish R ChopdaCarol A Paronis
Nov 26, 2015·Anesthesiology·Christina J Hayhurst, Marcel E Durieux
Dec 3, 2016·The Journal of Pharmacology and Experimental Therapeutics·Vanessa MinerviniCharles P France
Mar 23, 2017·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Suzanne NielsenBernard Le Foll
Jul 7, 2017·MMWR. Morbidity and Mortality Weekly Report·Gery P GuyDeborah Dowell
Aug 5, 2020·BMC Pharmacology & Toxicology·Ivan VelatViktor Čulić

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antihypertensive Agents: Mechanisms of Action

Antihypertensive drugs are used to treat hypertension (high blood pressure) which aims to prevent the complications of high blood pressure, such as stroke and myocardial infarction. Discover the latest research on antihypertensive drugs and their mechanism of action here.